AR106755A2 - Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos - Google Patents
Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismosInfo
- Publication number
- AR106755A2 AR106755A2 ARP160103545A ARP160103545A AR106755A2 AR 106755 A2 AR106755 A2 AR 106755A2 AR P160103545 A ARP160103545 A AR P160103545A AR P160103545 A ARP160103545 A AR P160103545A AR 106755 A2 AR106755 A2 AR 106755A2
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic group
- hydrogen
- group
- chlorine
- fluorine
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 5
- 229910052801 chlorine Inorganic materials 0.000 abstract 5
- 239000000460 chlorine Substances 0.000 abstract 5
- 229910052731 fluorine Inorganic materials 0.000 abstract 5
- 239000011737 fluorine Substances 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000007942 carboxylates Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de utilidad como inhibidores de proteína quinasas. También se proveen composiciones aceptables para uso farmacéutico que comprenden dichos compuestos y métodos para utilizar las composiciones en el tratamiento de diversas enfermedades, afecciones o trastornos. Reivindicación 1: Un compuesto, caracterizado porque es de la fórmula (1), o una sal aceptable para uso farmacéutico de los mismos, donde: R¹ es un grupo alifático C₁₋₆, donde R¹ está sustituido opcionalmente con hasta 2 grupos seleccionados independientemente entre -OR o -haloalquilo C₁₋₃; cada R es independientemente hidrógeno o C₁₋₄ alifático; R² es R, flúor o cloro; m es 0, 1 ó 2; y R³ es hidrógeno, un grupo alifático C₁₋₃, flúor o cloro. Reivindicación 17: Un compuesto, caracterizado porque es de la fórmula (2), o una sal del mismo, donde: PG es un grupo protector de aminos adecuado; Rᶻ es un grupo protector de carboxilatos adecuado; Rˣ y Rʸ son, independientemente entre sí, hidrógeno o un grupo alifático C₁₋₆ sustituido opcionalmente, o: Rˣ y Rʸ se toman juntos para formar un anillo de 5 - 7 miembros sustituido opcionalmente. Reivindicación 18: Un compuesto, caracterizado porque de la fórmula (3), o una sal del mismo, donde: R¹ es un grupo alifático C₁₋₆, donde R¹ está sustituido opcionalmente con hasta 2 grupos seleccionados independientemente entre -OR o -haloalquilo C₁₋₃; cada R es independientemente hidrógeno o un grupo alifático C₁₋₄; R³ es hidrógeno, un grupo alifático C₁₋₃, flúor o cloro; y L² es un grupo saliente adecuado. Reivindicación 19: Un compuesto, caracterizado porque es de la fórmula (4), o una sal del mismo, donde: R³ es hidrógeno, un grupo alifático C₁₋₃, flúor o cloro; y L¹ y L² son, independientemente entre sí, un grupo saliente adecuado. Reivindicación 20: Un compuesto, caracterizado porque es de la fórmula (5), o una sal del mismo, donde: PG es un grupo protector de amino adecuado; Rᶻ es un grupo protector de carboxilato adecuado; R¹ es un grupo alifático C₁₋₆, donde R¹ está sustituido opcionalmente con hasta 2 grupos seleccionados independientemente entre -O o -haloalquilo C₁₋₃; cada R es independientemente hidrógeno o un grupo alifático C₁₋₄; y R³ es hidrógeno, un grupo alifático C₁₋₃, flúor o cloro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57130904P | 2004-05-14 | 2004-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106755A2 true AR106755A2 (es) | 2018-02-14 |
Family
ID=35106760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101987A AR051735A1 (es) | 2004-05-14 | 2005-05-13 | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. |
| ARP160103545A AR106755A2 (es) | 2004-05-14 | 2016-11-18 | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101987A AR051735A1 (es) | 2004-05-14 | 2005-05-13 | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7354939B2 (es) |
| EP (5) | EP2799434B1 (es) |
| JP (1) | JP5132305B2 (es) |
| CN (1) | CN1976919A (es) |
| AR (2) | AR051735A1 (es) |
| AU (1) | AU2005245885B2 (es) |
| BR (1) | BRPI0511111A (es) |
| CA (1) | CA2566461C (es) |
| CY (1) | CY1122336T1 (es) |
| DK (1) | DK3305776T3 (es) |
| ES (4) | ES2751761T3 (es) |
| HK (2) | HK1203505A1 (es) |
| HU (1) | HUE047130T2 (es) |
| IL (1) | IL179207A0 (es) |
| LT (1) | LT3305776T (es) |
| MX (1) | MXPA06013209A (es) |
| NO (1) | NO20065727L (es) |
| NZ (1) | NZ551582A (es) |
| PL (1) | PL3305776T3 (es) |
| PT (1) | PT3305776T (es) |
| RU (1) | RU2376299C2 (es) |
| SI (1) | SI3305776T1 (es) |
| TW (1) | TW200607803A (es) |
| UA (1) | UA84930C2 (es) |
| WO (1) | WO2005113541A1 (es) |
| ZA (1) | ZA200609975B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE450530T1 (de) * | 2003-03-13 | 2009-12-15 | Vertex Pharma | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren |
| JP2007530595A (ja) * | 2004-03-26 | 2007-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋ２のピリジンインヒビターおよびそれらの使用 |
| RU2376299C2 (ru) * | 2004-05-14 | 2009-12-20 | Вертекс Фармасьютикалз, Инкорпорейтед | Пиррольные соединения в качестве ингибиторов erk протеинкиназ, их синтез и промежуточные соединения |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| EP1984331B1 (en) * | 2006-02-16 | 2010-10-20 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
| NZ581698A (en) * | 2007-06-05 | 2012-09-28 | Merck Sharp & Dohme | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| SG188179A1 (en) | 2008-02-21 | 2013-03-28 | Merck Sharp & Dohme | Compounds that are erk inhibitors |
| CN102146074B (zh) * | 2011-01-26 | 2013-02-06 | 江苏先声药物研究有限公司 | 吡咯衍生物的制备方法及应用 |
| WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
| US10634677B2 (en) | 2013-10-14 | 2020-04-28 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD |
| JPWO2015060368A1 (ja) | 2013-10-23 | 2017-03-09 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015095831A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mtor and erk inhibitors |
| WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
| JP6678583B2 (ja) * | 2013-12-20 | 2020-04-22 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置 |
| US20160310477A1 (en) * | 2013-12-20 | 2016-10-27 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type 1 and erk inhibitors |
| BR112016014481B1 (pt) * | 2013-12-20 | 2022-11-08 | Biomed Valley Discoveries, Inc | Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| ES2918375T3 (es) * | 2013-12-20 | 2022-07-15 | Biomed Valley Discoveries Inc | Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK |
| US11013743B2 (en) | 2013-12-20 | 2021-05-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of CDK and ERK inhibitors |
| WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
| CN116854662A (zh) | 2015-01-30 | 2023-10-10 | 生物医学谷探索股份有限公司 | C21H22Cl2N4O2的晶型 |
| CA3168216A1 (en) | 2015-01-30 | 2016-08-04 | Biomed Valley Discoveries, Inc. | Crystalline c21h22cl2n4o2 malonate |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| WO2016192064A1 (en) | 2015-06-03 | 2016-12-08 | Js Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
| US10479791B2 (en) * | 2015-06-03 | 2019-11-19 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as ERK inhibitors |
| WO2017068412A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| EP3170822A1 (en) | 2015-11-18 | 2017-05-24 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| CA3037064A1 (en) | 2016-10-05 | 2018-04-12 | Zeno Royalties & Milestones, LLC | Spirocyclic compounds |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| JP7332589B2 (ja) * | 2017-10-12 | 2023-08-23 | ノバルティス アーゲー | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| EP4212531A1 (en) | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| TW202400572A (zh) * | 2022-03-24 | 2024-01-01 | 美商生物醫學谷探索公司 | Erk的吡咯抑制劑之氘化類似物、其合成及其中間物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5565413A (en) * | 1994-12-06 | 1996-10-15 | Zeneca Limited | Substituted pyridyl phenyl ketone herbicides |
| US5472966A (en) * | 1995-03-29 | 1995-12-05 | Bristol-Myers Squibb Company | Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE60027718T2 (de) * | 1999-06-22 | 2007-05-16 | Takeda Pharmaceutical Co. Ltd. | Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| AU2003259153A1 (en) | 2002-07-18 | 2004-02-09 | Alan Deangelis | Substituted triazine kinase inhibitors |
| GB0217780D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| CA2495386C (en) * | 2002-08-14 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| ATE450530T1 (de) * | 2003-03-13 | 2009-12-15 | Vertex Pharma | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren |
| RU2376299C2 (ru) * | 2004-05-14 | 2009-12-20 | Вертекс Фармасьютикалз, Инкорпорейтед | Пиррольные соединения в качестве ингибиторов erk протеинкиназ, их синтез и промежуточные соединения |
-
2005
- 2005-05-13 RU RU2006144445/04A patent/RU2376299C2/ru active
- 2005-05-13 TW TW094115644A patent/TW200607803A/zh unknown
- 2005-05-13 LT LTEP17184079.6T patent/LT3305776T/lt unknown
- 2005-05-13 UA UAA200613208A patent/UA84930C2/ru unknown
- 2005-05-13 EP EP14163944.3A patent/EP2799434B1/en active Active
- 2005-05-13 AU AU2005245885A patent/AU2005245885B2/en active Active
- 2005-05-13 NZ NZ551582A patent/NZ551582A/en unknown
- 2005-05-13 MX MXPA06013209A patent/MXPA06013209A/es active IP Right Grant
- 2005-05-13 BR BRPI0511111-0A patent/BRPI0511111A/pt not_active IP Right Cessation
- 2005-05-13 PT PT171840796T patent/PT3305776T/pt unknown
- 2005-05-13 US US11/128,870 patent/US7354939B2/en not_active Ceased
- 2005-05-13 HU HUE17184079A patent/HUE047130T2/hu unknown
- 2005-05-13 ES ES17184079T patent/ES2751761T3/es active Active
- 2005-05-13 CA CA2566461A patent/CA2566461C/en active Active
- 2005-05-13 EP EP17184079.6A patent/EP3305776B1/en active Active
- 2005-05-13 CN CNA200580021418XA patent/CN1976919A/zh active Pending
- 2005-05-13 ES ES14163944.3T patent/ES2651439T3/es active Active
- 2005-05-13 JP JP2007513432A patent/JP5132305B2/ja active Active
- 2005-05-13 EP EP19199330.2A patent/EP3608315B1/en active Active
- 2005-05-13 AR ARP050101987A patent/AR051735A1/es not_active Application Discontinuation
- 2005-05-13 EP EP21190432.1A patent/EP3943489A1/en active Pending
- 2005-05-13 DK DK17184079T patent/DK3305776T3/da active
- 2005-05-13 ES ES05748073.3T patent/ES2513965T3/es active Active
- 2005-05-13 WO PCT/US2005/016902 patent/WO2005113541A1/en active Application Filing
- 2005-05-13 EP EP05748073.3A patent/EP1753738B1/en active Active
- 2005-05-13 SI SI200532267T patent/SI3305776T1/sl unknown
- 2005-05-13 ZA ZA200609975A patent/ZA200609975B/en unknown
- 2005-05-13 ES ES19199330T patent/ES2897422T3/es active Active
- 2005-05-13 PL PL17184079T patent/PL3305776T3/pl unknown
-
2006
- 2006-11-13 IL IL179207A patent/IL179207A0/en unknown
- 2006-12-12 NO NO20065727A patent/NO20065727L/no not_active Application Discontinuation
-
2013
- 2013-08-23 US US14/544,396 patent/USRE46097E1/en active Active
-
2015
- 2015-05-04 HK HK15104226.1A patent/HK1203505A1/xx unknown
-
2016
- 2016-06-28 US US15/195,021 patent/USRE47318E1/en active Active
- 2016-11-18 AR ARP160103545A patent/AR106755A2/es active IP Right Grant
-
2018
- 2018-05-15 HK HK18106295.9A patent/HK1247910A1/zh unknown
-
2019
- 2019-03-25 US US16/363,905 patent/USRE48266E1/en active Active
- 2019-12-03 CY CY20191101265T patent/CY1122336T1/el unknown
-
2020
- 2020-10-15 US US17/071,566 patent/USRE49500E1/en active Active
-
2023
- 2023-02-22 US US18/173,004 patent/US20230183276A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106755A2 (es) | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR033306A1 (es) | Compuestos | |
| PA8609201A1 (es) | Piridinonas sustituidas | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| CO7160015A2 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
| UY31468A1 (es) | Derivados bis-(sulfonilamino) en terapia 065 | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| CO6270311A2 (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| GT200600143A (es) | Fenilacetamidas apropiadas como inhibidores de la proteina kinasa | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| CL2004000076A1 (es) | Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi | |
| AR038326A1 (es) | Antibacterianos feniloxazolidinonas sustituidos con heterociclicos biciclicos y composiciones relacionadas y metodos | |
| AR039868A1 (es) | Inhibidores selectivos de la enzima kalikreina plasmatica | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| AR059086A1 (es) | Derivados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de cinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |